CME in Minutes: Education in Cardiology & Pulmonology - Eileen Wang, MD, MPH - Breathing Life Into Type 2 Asthma: Advancing Clinical Remission With Biologics

Eileen Wang, MD, MPH - Breathing Life Into Type 2 Asthma: Advancing Clinical Remission With Biologics

08/05/24 • 13 min

CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/WMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. Upon completion of this activity, participants should be better able to: Define “clinical remission” of asthma; and Review the impact of approved biologics for the treatment of patients with T2 asthma on clinical remission; Outline strategies for incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. This activity is intended for US healthcare professionals only.

Previous Episode

Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.

Next Episode

undefined - Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

Cecelia Damask, DO - Evidence-Based Approaches to Sequencing and Switching Biologic Therapies in Patients With CRSwNP and Comorbidities

Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.